Prostate Compass
A guided decision tool for men newly diagnosed with intermediate-risk prostate cancer that compares focal therapy, surgery, and radiotherapy with side-effect tradeoffs in plain language.
Men newly diagnosed with intermediate-risk prostate cancer weighing treatment options
- Personalized treatment comparison based on your PSA, Gleason score, and MRI findings
- Side-effect tradeoffs (incontinence, sexual function) shown in plain, relatable terms
- Locator for the 10 NHS focal therapy centres plus vetted private clinic options
- "Questions to ask your urologist" generator from your specific diagnosis
The 10-year NHS trial just published showing focal therapy matches surgery with half the side effects, but the postcode lottery forces patients to self-educate to even be offered it.
NHS 10-year Imperial College trial (n=3,477) confirms focal therapy matches surgery with half the side effects, generating major BBC/Imperial NHS coverage in 2025; ~56k UK prostate cancer diagnoses/year with intermediate-risk a large subset, and patients are highly motivated during diagnosis.Prostate cancer trial using focal therapy has fewer side effects ↗New study shows focal therapy effectively treats prostate cancer ↗
Direct competitors exist: VUMC CEASAR decision tool (US academic, weak on focal therapy), ProFocal Decision Tool (socalfocal.com, regional SoCal provider site), Bridgeable's Therachoice, and prostatecancerfree.org — but none is a polished, plain-language UK-facing consumer tool prominently featuring focal therapy.Online Prostate Cancer Treatment Decision-Making Tool ↗ProFocal Decision Tool — Focal therapy for prostate cancer: explained ↗Compare Prostate Cancer Treatments ↗
Difficult: newly diagnosed patients are anxious, NHS pathway is free, and established medical decision aids (CEASAR, ProFocal) are free; plausible revenue is limited to provider sponsorship, clinic referrals, or premium tiers — none clearly validated in this niche.Online Prostate Cancer Treatment Decision-Making Tool ↗Helping cancer patients make treatment decisions - Bridgeable ↗
Prostate cancer incidence is rising with aging populations; treatment decisions remain multi-option and contested; clinical evidence base (focal therapy trials, genomics) continues to evolve, keeping a decision-comparison tool relevant for many years.Study Reports 10-Year Outcomes of Focal Therapy for Prostate Cancer ↗
A web-based comparison tool is technically straightforward, but medical accuracy, clinician review, MHSA/UK medical-device regulatory classification, and liability concerns materially raise the bar; sourcing up-to-date outcomes data also requires ongoing effort.An online decision aid for patients with prostate cancer evaluating ↗